Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Disease area: Respiratory infections

Abstract

Aim:The aim of study is to investigate the incidence of tuberculosis during the treatment in patients taking anti-tumor necrosis factor alpha(anti TNF-α).
Material-method:The patients with rheumotoid arthritis,ankylosing spondylitis,jeuvenil rheumotoid arthritis or psoriatic arthiritis who were planned to treat with anti TNF-α or taking anti TNF-α therapy and sent to our pulmonary diseases outpatient clinic between July 2007-February 2010 were included in this study.PPD tests and chest X-rays were evaluated.Chest x-rays were examined for tuberculous sequelea and the patients suspicious for tuberculous sequelea were asked for contact with a tuberculosis case,physical examinations were done and their sputum was examined for acid-fast bacilli.
Results:Two hundred and twenty patients were included in the study.Anti TNF-α therapy was given the first time in 168 patients.Fifty two patients were already taking anti TNF-α therapy and directed to our outpatient clinic for follow-up.One hundred seventy nine patients were followed up regularly,41 patients did not continue follow-up and were excluded.Median follow-up period was 17 months(max:31; min:3 months).Two patients were diagnosed as tuberculosis during antiTNF- α therapy.
Conclusion:According to the data of ministry of health,the incidence of tuberculosis is 0.0026% in our country.In our study it is estabilished as 1.1%.When compared with the community,the incidence of tuberculosis is increased with antiTNF- α therapy.The blockade of TNF which one of the fundamental cytokins in human defense system leads to an increase in tuberculosis infection.The patients who were planned to treat with anti TNF-α should be monitored closely for tuberculosis during the treatment.

Rating:

Share or cite this content

Citations should be made in the following way:
C. Dogan, N. Kiral, S. Cömert, A. Fidan, B. Salepci, B. Caglayan (Istanbul, Turkey). The incidence of tuberculosis in patients taking anti TNF alpha therapy. Eur Respir J 2011; 38: Suppl. 55, 1945

Member's Comments

No comment yet.

Related content which might interest you: Our approach about latent tuberculosis infection in patients who are given anti-TNF alpha therapy Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009 An evaluation of the use of a negative interferon gamma release assay for tuberculosis screening before TNF antagonist therapy Source: Eur Respir J 2014; 44: 1369-1372 Year: 2014 Observation results of 484 patients that use TNF alfa inhibitor in respect of the risk of tuberculosis Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 Isoniazid protection and risk of tuberculosis in patients who used anti tumor necrosis factor-alpha treatment Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007 Follow up results of patients receiving anti tumor necrosis antagonists and evaluation of risk of tuberculosis Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009 Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Diagnostic performance of the interferon gamma release assay in elderly patients and clinical factors to support the diagnosis of active tuberculosis Source: Annual Congress 2012 - Tuberculosis and immunologic assays Year: 2012 IP-10 decreases during antituberculous treatment in children with active tuberculosis. Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020 Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 Does anti TNF-α treatment increase tuberculosis risk? Source: Eur Respir J 2007; 30: Suppl. 51, 281s Year: 2007 The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 542s Year: 2006 Characteristics of new tuberculosis cases diagnosed during treatment with TNF-alpha antagonists Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009 The value of cellular interferon – gamma assays for TB diagnosis in immunocompetent and immunocompromised patients Source: Annual Congress 2007 - Gamma-interferon-based tests to diagnose tuberculosis infection and disease Year: 2007 Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy Source: Eur Respir J 2014; 44: 1289-1295 Year: 2014 What is the best test to detect latent tuberculosis infection in sarcoidosis patients? – Comparison between two commercially available interferon gamma release assays Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 LATE-BREAKING ABSTRACT: The performance of flow cytometry in the diagnosis of latent tuberculosis infection in patients under treatment with anti-TNFa and other biological agents Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013 Miliary tuberculosis during treatment with anti TNF alpha - a report of four cases Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013 Relationship of interleukin 10 1082 G/A gene polymorphism with the duration of nephrotoxic onset due to anti tuberculosis drugs in multi drug resistant tuberculosis patients Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019 A combinatorial dual-immunoassay predicts reactivation risk for patients with previously incomplete treatment for latent tuberculosis infection Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016